BMS-663068

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

26 competitors in HIV Infections

#DrugCompanyPhaseTrials

1

Cabenuva

GSK

Phase 3

52

Tivicay

GSK

Phase 3

43

Biktarvy

Gilead

Phase 3

24

Sunlenca

Gilead

Phase 3

25

CAB LA

GSK

Phase 3

56

Fostemsavir

GSK

Phase 3

27

Rhuph20

Bristol-Myers Squibb

Phase 2

28

Teropavimab

Gilead

Phase 3

19

Zinlirvimab

Gilead

Phase 3

110

APRETUDE

GSK

Phase 3

1Show 8 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Interaction4 trials

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Completed·GSK·Phase 1·NCT02480894·112 enrolled

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Completed·GSK·Phase 1·NCT02277600·32 enrolled

Drug-drug Interaction (DDI) Rifabutin

Completed·GSK·Phase 1·NCT02138084·102 enrolled

Show 1 more trial

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Completed·GSK·Phase 1·NCT02480881·26 enrolled

Tics2 trials

Study on Pharmacokinetics

Completed·GSK·Phase 1·NCT02234882·50 enrolled

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Completed·GSK·Phase 1·NCT02164045·38 enrolled

Buprenorphine1 trial

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Completed·GSK·Phase 1·NCT02666001·32 enrolled

Hepatic Impairment1 trial

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Completed·GSK·Phase 1·NCT02467335·52 enrolled

Immunodeficiency1 trial

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Completed·GSK·Phase 2·NCT01384734·254 enrolled

8 more indications

MPA1 trial

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Completed·GSK·Phase 1·NCT02859259·14 enrolled

HIV-11 trial

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

Completed·GSK·Phase 2·NCT01009814·50 enrolled

Intravenous1 trial

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Completed·GSK·Phase 1·NCT02805556·36 enrolled

Function1 trial

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Completed·GSK·Phase 1·NCT02674581·30 enrolled

ART1 trial

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Completed·GSK·Phase 1·NCT02508064·27 enrolled

Gastric1 trial

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Completed·GSK·Phase 1·NCT02666053·72 enrolled

HIV Infections1 trial

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)

Active, not recruiting·GSK·Phase 3·NCT02362503·371 enrolled

Unspecified1 trial

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Completed·GSK·Phase 1·NCT02063360·42 enrolled

Details

Drug Info

Related News